Baseball fans, get ready for a surprising move that could shake up the Pirates' roster! In a bold offseason decision, the Pittsburgh Pirates have inked a $1.5 million, one-year deal with veteran pitcher José Urquidy, adding a layer of intrigue to their pitching staff. But here's where it gets interesting: this agreement, confirmed by an anonymous source close to the negotiations, hinges on Urquidy passing a physical—a detail that raises questions about his recent injury history. And this is the part most people miss: Urquidy, a 30-year-old right-hander, isn't just any addition; he brings both experience and flexibility, as he can be optioned to the minors if needed. This move pairs him with NL Cy Young Award winner Paul Skenes, creating a dynamic contrast between proven talent and rising stardom.
Urquidy’s journey to Pittsburgh hasn’t been without challenges. After undergoing Tommy John surgery in June 2024 while with the Houston Astros, he signed a $1 million deal with the Detroit Tigers last March, making a brief return to the majors in September. His 2023 stats—a 7.71 ERA over 2 1/3 innings in two relief appearances—might not jump off the page, but his six-year MLB career tells a more compelling story. With a 27-16 record and a 4.00 ERA across 70 starts and 11 relief outings for the Astros and Tigers, Urquidy has proven he can handle high-pressure situations, including a solid 4.08 ERA in 15 postseason appearances (8 starts).
But here’s the controversial part: Is this a calculated risk or a desperate move by the Pirates? Some might argue that relying on a pitcher coming off major surgery is a gamble, especially with his recent performance. Others see it as a low-risk, high-reward play for a team looking to bolster its depth. What do you think? Is Urquidy’s addition a smart strategy, or are the Pirates setting themselves up for disappointment? Let’s debate it in the comments—this is one deal that’s sure to spark differing opinions!
